Category: Accent

  • PharmaShots Weekly Snapshots (October 18 – 22, 2021)

    LEO Reports 16-week Results of Tralokinumab in P-III ECZTRA 6 Trial for the Treatment of Moderate-to-Severe Atopic Dermatitis Published: 22 Oct, 2021 | Tags: LEO, Tralokinumab, P-III, ECZTRA 6 Trial, Atopic Dermatitis Marinomed Biotech Signs a License Agreement with Luoxin to Commercialize Budesolv (budesonide nasal spray) in Greater China Published: 22 Oct, 2021 | Tags: […]

  • Ipsen Signs an Exclusive WW Collaboration with Accent to Develop and Commercialize METTL3 Program

    Shots: Accent to receive ~$446M including up front, pre-clinical, clinical, regulatory, and sales-based milestone along with royalties Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor program The collaboration combines Accent’s expertise in RMP-targeting therapeutics with Ipsen’s capabilities to develop and commercialize transformative oncology medicines for the treatment of AML […]